SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2844The drug development pipeline must be pretty scratch-empty, when the only thing Icebrg-4/26/2007
2843Millennium Pharma (MLNM.O): More Cautious After Survey; Lowering PT to $9 (1 RIcebrg-4/25/2007
2842Press Release Source: Millennium Pharmaceuticals, Inc. Millennium Discovers Bioidos-4/17/2007
2841Public release date: 15-Apr-2007 Contact: Elizabeth Zimmermann newsbureau@mayo.Ian@SI-4/15/2007
2840Diminished feedback regulation of proteasome expression and resistance to proteaIcebrg-4/15/2007
2839Molecular dissection of hyperdiploid multiple myeloma by gene expression profiliIcebrg-4/6/2007
2838Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solidIcebrg-4/6/2007
2837Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung CaIcebrg-4/6/2007
2836Believe they're talking about Revlimid Public release date: 4-Apr-2007 ] CIan@SI-4/4/2007
2835[Bortezomib and MEK 1/2 inhibitors versus breast cancer] >>Mol Pharmacol.tuck-4/1/2007
2834NICE applauded for choosing to rethink Velcade review Charity groups in the UK,Icebrg-3/31/2007
2833Given the activity shown in combination studies, it seems we a due for a move inD.Lu-3/30/2007
2832Assessment of Apoptosis-Inducing Effects of Docetaxel Combined with the ProteasoIcebrg-3/29/2007
2831JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, Icebrg-3/28/2007
2830CuraGen Corp (CRGN) and TopoTarget announce the initiation of patient dosing in Ian@SI-3/27/2007
2829Targeted therapy of multiple myeloma based upon tumor-microenvironmental interacIcebrg-3/26/2007
2828Proteasome Inhibition Specifically Sensitizes Leukemic Cells to Anthracyclin-IndIcebrg-3/23/2007
2827TNF potentiates anticancer activity of bortezomib (Velcade(R)) through reduced eIcebrg-3/23/2007
2826[SAHA induces apoptosis in hepatoma cells and synergistically interacts with Veltuck-3/19/2007
2825The Proteasome Inhibitor Bortezomib Acts Independently of p53 and Induces Cell DIcebrg-3/19/2007
2824Bortezomib Is Active in Patients With Untreated or Relapsed Waldenstrom's MaIcebrg-3/15/2007
2823Item 8.01 Other Events. On March 13, 2007, the United States Patent and TrademaIcebrg-3/13/2007
2822We presented data at ASH 2006 from Phase 1b clinical trial of tanespimycin plus Icebrg-3/13/2007
2821Use of systemic proteasome inhibition as an immune-modulating agent in disease. Icebrg-3/12/2007
2820[Bortezomib and PR-171 have antiproliferative and proapoptotic effects on primartuck-3/9/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News